Seer, Inc. (SEER)

NASDAQ: SEER · IEX Real-Time Price · USD
10.69
-2.62 (-19.68%)
At close: Aug 11, 2022 4:00 PM
10.64
-0.05 (-0.47%)
Pre-market: Aug 12, 2022 8:13 AM EDT
-19.68%
Market Cap 669.32M
Revenue (ttm) 12.15M
Net Income (ttm) -84.59M
Shares Out 62.61M
EPS (ttm) -1.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 749,438
Open 12.28
Previous Close 13.31
Day's Range 9.75 - 13.09
52-Week Range 6.44 - 45.85
Beta n/a
Analysts Buy
Price Target 15.30 (+43.1%)
Earnings Date Aug 9, 2022

About SEER

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and b... [Read more...]

Industry Life Sciences Tools & Services
IPO Date Dec 4, 2020
Employees 118
Stock Exchange NASDAQ
Ticker Symbol SEER
Full Company Profile

Financial Performance

In 2021, Seer, Inc.'s revenue was $6.62 million, an increase of 908.69% compared to the previous year's $656,000. Losses were -$71.17 million, 117.1% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for SEER stock is "Buy." The 12-month stock price forecast is 15.3, which is an increase of 43.12% from the latest price.

Price Target
$15.3
(43.12% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Seer, Inc. (SEER) Reports Q2 Loss, Tops Revenue Estimates

Seer, Inc. (SEER) delivered earnings and revenue surprises of 5.13% and 17.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Seer Reports Second Quarter 2022 Financial Results

Company launches novel proteogenomics workflow with the Proteograph™ Analysis Suite 2.0, further demonstrates the power of its technology with new customer data, and advances key partnerships Company la...

Seer Launches First-of-its-kind Proteogenomics Workflow to Link Genetic Changes with Protein Variants with Proteograp...

Scalable, high-resolution, sample-specific analysis brings genomics and proteomics together to enable novel biological insights with the click of a button Scalable, high-resolution, sample-specific anal...

Seer to Report Second Quarter 2022 Financial Results on August 9, 2022

REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financi...

Seer, Inc. (SEER) Stock Jumps 12.9%: Will It Continue to Soar?

Seer, Inc. (SEER) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in...

Seer, Inc. (SEER) Reports Q1 Loss, Tops Revenue Estimates

Seer, Inc. (SEER) delivered earnings and revenue surprises of 7.32% and 18.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Seer Reports First Quarter 2022 Financial Results

Demonstrated solid commercial traction with continued robust interest in the Proteograph Product Suite Demonstrated solid commercial traction with continued robust interest in the Proteograph Product Suite

Seer to Present at the BofA Securities 2022 Healthcare Conference

REDWOOD CITY, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company wil...

Analysts Estimate Seer, Inc. (SEER) to Report a Decline in Earnings: What to Look Out for

Seer, Inc. (SEER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seer to Report First Quarter Financial Results on May 4, 2022

REDWOOD CITY, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financ...

ROSEN, A LEADING LAW FIRM, Encourages Seer, Inc. Investors With Losses to Inquire About Class Action Investigation - ...

NEW YORK , April 5, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Seer, Inc. (NASDAQ: SEE...

SEER SHAREHOLDER ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Seer, Inc. Investors with Losses to Inquire ...

New York, New York--(Newsfile Corp. - April 1, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of See...

Seer Announces Appointment of Scott D. Thomas as Chief Commercial Officer

Seasoned life sciences executive adds extensive global sales expertise to drive commercial efforts Seasoned life sciences executive adds extensive global sales expertise to drive commercial efforts

Seer Announces Publication of Seminal Study Demonstrating Superior Performance of Technology Platform for Deep, Unbia...

REDWOOD CITY, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) today announced the publication of a study demonstrating the performance of the technology platform underlying the Prot...

Seer Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Full Year 2022 Outlook

Demonstrated tangible market progress and shipped 17 instruments through year end 2021 Demonstrated tangible market progress and shipped 17 instruments through year end 2021

Seer to Present at the Cowen 42nd Annual Health Care Conference

REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will...

Seer, Inc. (SEER) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Seer, Inc. (SEER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seer to Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2021

REDWOOD CITY, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financi...

Updated: Seer Announces Broad Commercial Release of the Proteograph™ Product Suite and Launches Centers of Excellence...

Company has already booked multiple orders and established COEs in three major geographies Company has already booked multiple orders and established COEs in three major geographies

Seer, Discovery Life Sciences and SCIEX Announce First-Of-Its-Kind Proteogenomics Consortium for Large-Scale Studies

Delivery of 100,000 samples of capacity annually to the market, empowering genomics researchers to add deep, unbiased proteomics analysis to their studies Delivery of 100,000 samples of capacity annuall...

Seer Announces Broad Commercial Release of the Proteograph™ Product Suite and Launches Centers of Excellence Program

Company has already booked multiple orders and established COEs in three major geographies Company has already booked multiple orders and established COEs in three major geographies

Seer to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will...

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Seer, Inc. Investors with Losses in Excess of $100K to Inquire ...

NEW YORK, Dec. 20, 2021 /PRNewswire/ -- WHY:  Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Seer, Inc. (NASDA...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Seer, Inc. and Encourages Inves...

Los Angeles, California--(Newsfile Corp. - December 3, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Se...

Seer Appoints Meeta Gulyani to its Board of Directors

REDWOOD CITY, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Mee...